GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between KRas and GSK-3. To further elucidate the roles o...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrams, Stephen L., Akula, Shaw M., Meher, Akshaya K., Steelman, Linda S., Gizak, Agnieszka, Duda, Przemysław, Rakus, Dariusz, Martelli, Alberto M., Ratti, Stefano, Cocco, Lucio, Montalto, Giuseppe, Cervello, Melchiorre, Ruvolo, Peter, Libra, Massimo, Falzone, Luca, Candido, Saverio, McCubrey, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067414/
https://www.ncbi.nlm.nih.gov/pubmed/33917370
http://dx.doi.org/10.3390/cells10040816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067414/
https://www.ncbi.nlm.nih.gov/pubmed/33917370
http://dx.doi.org/10.3390/cells10040816

Ejemplares similares